Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Histopathology. 2018 Nov;73(5):748-757. doi: 10.1111/his.13696. Epub 2018 Aug 14.
Basal and luminal molecular subgroups of muscle-invasive urothelial carcinoma (UC) can be recognised by the use of immunohistochemical markers. Studies have shown that responses to chemotherapy and outcomes differ among these subtypes. High-grade UC of the bladder is an immunogenic neoplasm that induces a substantial intratumoral and peritumoral immune response; the phenotype of infiltrating immune cells may yield prognostic information and predict response to therapy. In this study, we aimed to correlate the immunohistochemical phenotype of high-grade UC with immune microenvironment composition.
Two hundred and thirty-five cases of high-grade UC treated with cystectomy were reviewed. Clinicopathological variables for each case were recorded, and disease-free survival at last follow-up was calculated. Invasive front inflammation and tumour-infiltrating lymphocytes were scored for each case. Two hundred and seven cases were used to construct a triplicate-core tissue microarray (TMA), with sections stained for cytokeratin (CK) 5/6 and GATA3. Of the evaluable cases, 167 were designated as luminal (CK5/6- and GATA3+) and 29 as basal (CK5/6+ and GATA3-). Additional sequential TMA sections were stained for CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, programmed cell death protein 1 (PD-1), and programmed death-ligand 1 (PD-L1) (SP263). Basal-subtype tumours showed a trend towards worse disease-specific survival (P = 0.078). There were statistically significant associations between basal subtype and CD8 expression (P = 0.008), PD-1 expression (P = 0.001), and PD-L1 expression (P = 0.014). Lower CD4/CD8 and increased CD8/FOXP3 ratios (P = 0.047 and P = 0.031, respectively) were also identified in the basal-subtype group.
Basal-subtype high-grade UC has an abundance of CD8+ T cells with increased expression of inhibitory markers, indicative of a 'hot' immunophenotype.
肌层浸润性尿路上皮癌(UC)的基底和腔面分子亚群可通过免疫组织化学标志物识别。研究表明,这些亚型对化疗的反应和结局不同。高级别膀胱癌是一种免疫原性肿瘤,会引起肿瘤内和肿瘤周围的大量免疫反应;浸润免疫细胞的表型可能提供预后信息,并预测对治疗的反应。在这项研究中,我们旨在将高级别 UC 的免疫组化表型与免疫微环境组成相关联。
对接受膀胱切除术治疗的 235 例高级别 UC 病例进行了回顾性分析。记录了每个病例的临床病理变量,并计算了最后一次随访时的无病生存率。对每个病例的侵袭前沿炎症和肿瘤浸润淋巴细胞进行了评分。207 例病例被用于构建三重复组织微阵列(TMA),并用细胞角蛋白(CK)5/6 和 GATA3 染色切片。在可评估的病例中,167 例被指定为腔面(CK5/6+和 GATA3+),29 例为基底(CK5/6+和 GATA3-)。额外的连续 TMA 切片用 CD3、CD4、CD8、CD20、CD68、CD163、FOXP3、程序性细胞死亡蛋白 1(PD-1)和程序性死亡配体 1(PD-L1)(SP263)染色。基底亚型肿瘤的疾病特异性生存率有下降趋势(P=0.078)。基底亚型与 CD8 表达(P=0.008)、PD-1 表达(P=0.001)和 PD-L1 表达(P=0.014)之间存在统计学显著关联。在基底亚型组中,还发现 CD4/CD8 比值降低和 CD8/FOXP3 比值增加(分别为 P=0.047 和 P=0.031)。
基底亚型高级别 UC 具有丰富的 CD8+T 细胞,其抑制性标志物表达增加,提示为“热”免疫表型。